Literature DB >> 29059504

Intersection of Proteomics and Genomics to "Solve the Unsolved" in Rare Disorders such as Neurodegenerative and Neuromuscular Diseases.

Andreas Roos1,2, Rachel Thompson1, Rita Horvath1, Hanns Lochmüller1, Albert Sickmann2,3,4.   

Abstract

Despite recent rapid advances in sequencing technologies, a significant proportion of patients with rare genetic disorders do not receive a genetic diagnosis after exhaustive testing, and even fewer have a potential therapeutic target identified. Taking rare neuromuscular and neurodegenerative disorders as a paradigm that can be extended to other rare Mendelian disorders, this viewpoint explores the opportunities that are brought about by the integration of genomics and proteomics, as well as the limitations and remaining challenges of this newly emerging field of proteogenomics. The relevance of combining proteomic findings with genetic results for diagnosis and gene discovery is illustrated, highlighting the insights the combined analysis provides into the underlying biology and aetiology as well as the limitations of the experimental techniques. A final discussion focuses on the importance of mechanisms to enable the sharing, reuse, and analysis of source experimental data and describes some of the international initiatives that are making progress in this area.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  data sharing; neuromuscular diseases; omics data intersection; proteogenomics; rare diseases

Mesh:

Year:  2017        PMID: 29059504     DOI: 10.1002/prca.201700073

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  12 in total

Review 1.  [Genomics and proteomics in the research of neuromuscular diseases].

Authors:  Andrea Gangfuß; Ulrike Schara-Schmidt; Andreas Roos
Journal:  Nervenarzt       Date:  2021-10-07       Impact factor: 1.214

Review 2.  Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy.

Authors:  Kay Ohlendieck; Dieter Swandulla
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 4.458

3.  Biochemical and pathological changes result from mutated Caveolin-3 in muscle.

Authors:  José Andrés González Coraspe; Joachim Weis; Mary E Anderson; Ute Münchberg; Kristina Lorenz; Stephan Buchkremer; Stephanie Carr; René Peiman Zahedi; Eva Brauers; Hannah Michels; Yoshihide Sunada; Hanns Lochmüller; Kevin P Campbell; Erik Freier; Denisa Hathazi; Andreas Roos
Journal:  Skelet Muscle       Date:  2018-08-28       Impact factor: 4.912

4.  Neuromuscular Junction Changes in a Mouse Model of Charcot-Marie-Tooth Disease Type 4C.

Authors:  Silvia Cipriani; Vietxuan Phan; Jean-Jacques Médard; Rita Horvath; Hanns Lochmüller; Roman Chrast; Andreas Roos; Sally Spendiff
Journal:  Int J Mol Sci       Date:  2018-12-17       Impact factor: 5.923

5.  Protein signature of human skin fibroblasts allows the study of the molecular etiology of rare neurological diseases.

Authors:  Andreas Hentschel; Artur Czech; Ute Münchberg; Erik Freier; Ulrike Schara-Schmidt; Albert Sickmann; Jens Reimann; Andreas Roos
Journal:  Orphanet J Rare Dis       Date:  2021-02-09       Impact factor: 4.123

6.  Autosomal recessive variants in TUBGCP2 alter the γ-tubulin ring complex leading to neurodevelopmental disease.

Authors:  Serdal Gungor; Yavuz Oktay; Semra Hiz; Álvaro Aranguren-Ibáñez; Ipek Kalafatcilar; Ahmet Yaramis; Ezgi Karaca; Uluc Yis; Ece Sonmezler; Burcu Ekinci; Mahmut Aslan; Elmasnur Yilmaz; Bilge Özgör; Sunitha Balaraju; Nora Szabo; Steven Laurie; Sergi Beltran; Daniel G MacArthur; Denisa Hathazi; Ana Töpf; Andreas Roos; Hanns Lochmuller; Isabelle Vernos; Rita Horvath
Journal:  iScience       Date:  2020-12-30

Review 7.  The Increasing Impact of Translational Research in the Molecular Diagnostics of Neuromuscular Diseases.

Authors:  Dèlia Yubero; Daniel Natera-de Benito; Jordi Pijuan; Judith Armstrong; Loreto Martorell; Guerau Fernàndez; Joan Maynou; Cristina Jou; Mònica Roldan; Carlos Ortez; Andrés Nascimento; Janet Hoenicka; Francesc Palau
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

Review 8.  Could Proteomics Become a Future Useful Tool to Shed Light on the Mechanisms of Rare Neurodegenerative Disorders?

Authors:  Maddalena Cagnone; Anna Bardoni; Paolo Iadarola; Simona Viglio
Journal:  High Throughput       Date:  2018-01-10

9.  Clinical presentation and proteomic signature of patients with TANGO2 mutations.

Authors:  Nadja Mingirulli; Angela Pyle; Denisa Hathazi; Charlotte L Alston; Nicolai Kohlschmidt; Gina O'Grady; Leigh Waddell; Frances Evesson; Sandra B T Cooper; Christian Turner; Jennifer Duff; Ana Topf; Delia Yubero; Cristina Jou; Andrés Nascimento; Carlos Ortez; Angels García-Cazorla; Claudia Gross; Maria O'Callaghan; Saikat Santra; Maryanne A Preece; Michael Champion; Sergei Korenev; Efsthatia Chronopoulou; Majumdar Anirban; Germaine Pierre; Daniel McArthur; Kyle Thompson; Placido Navas; Antonia Ribes; Frederic Tort; Agatha Schlüter; Aurora Pujol; Raquel Montero; Georgia Sarquella; Hanns Lochmüller; Cecilia Jiménez-Mallebrera; Robert W Taylor; Rafael Artuch; Janbernd Kirschner; Sarah C Grünert; Andreas Roos; Rita Horvath
Journal:  J Inherit Metab Dis       Date:  2019-08-13       Impact factor: 4.982

10.  Exome reanalysis and proteomic profiling identified TRIP4 as a novel cause of cerebellar hypoplasia and spinal muscular atrophy (PCH1).

Authors:  Andreas Roos; Rita Horvath; Ana Töpf; Angela Pyle; Helen Griffin; Leslie Matalonga; Katherine Schon; Albert Sickmann; Ulrike Schara-Schmidt; Andreas Hentschel; Patrick F Chinnery; Heike Kölbel
Journal:  Eur J Hum Genet       Date:  2021-06-01       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.